TW202617173A - Mazdutide的應用 - Google Patents

Mazdutide的應用

Info

Publication number
TW202617173A
TW202617173A TW114124620A TW114124620A TW202617173A TW 202617173 A TW202617173 A TW 202617173A TW 114124620 A TW114124620 A TW 114124620A TW 114124620 A TW114124620 A TW 114124620A TW 202617173 A TW202617173 A TW 202617173A
Authority
TW
Taiwan
Prior art keywords
dose
drug
weeks
week
once
Prior art date
Application number
TW114124620A
Other languages
English (en)
Chinese (zh)
Inventor
安培
鄧煥
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202617173A publication Critical patent/TW202617173A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW114124620A 2021-06-25 2022-06-23 Mazdutide的應用 TW202617173A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110711050.0 2021-06-25
CN202110711050 2021-06-25

Publications (1)

Publication Number Publication Date
TW202617173A true TW202617173A (zh) 2026-05-01

Family

ID=84544128

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114124620A TW202617173A (zh) 2021-06-25 2022-06-23 Mazdutide的應用
TW111123396A TW202300171A (zh) 2021-06-25 2022-06-23 Mazdutide的應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111123396A TW202300171A (zh) 2021-06-25 2022-06-23 Mazdutide的應用

Country Status (9)

Country Link
US (1) US20240293513A1 (cg-RX-API-DMAC10.html)
EP (1) EP4360641A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524273A (cg-RX-API-DMAC10.html)
KR (1) KR20240027053A (cg-RX-API-DMAC10.html)
CN (1) CN117597135A (cg-RX-API-DMAC10.html)
AU (1) AU2022298841A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224043A1 (cg-RX-API-DMAC10.html)
TW (2) TW202617173A (cg-RX-API-DMAC10.html)
WO (1) WO2022268174A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023281591A1 (en) * 2022-06-01 2025-01-02 Innovent Biologics (Suzhou) Co., Ltd. Treatment method using mazdutide
EP4788362A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
EP4788356A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating adolescent obesity
WO2025098422A1 (zh) * 2023-11-07 2025-05-15 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
AU2023281591A1 (en) * 2022-06-01 2025-01-02 Innovent Biologics (Suzhou) Co., Ltd. Treatment method using mazdutide

Also Published As

Publication number Publication date
US20240293513A1 (en) 2024-09-05
JP2024524273A (ja) 2024-07-05
TW202300171A (zh) 2023-01-01
EP4360641A4 (en) 2025-10-22
CA3224043A1 (en) 2022-12-29
CN117597135A (zh) 2024-02-23
EP4360641A1 (en) 2024-05-01
AU2022298841A1 (en) 2024-01-25
WO2022268174A1 (zh) 2022-12-29
KR20240027053A (ko) 2024-02-29

Similar Documents

Publication Publication Date Title
EA201591907A1 (ru) Ингибитор киназ
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
JP2017513836A5 (cg-RX-API-DMAC10.html)
WO2007007919A3 (en) Heterocyclic janus kinase 3 inhibitors
JP2017502940A5 (cg-RX-API-DMAC10.html)
MA38078A1 (fr) Dérivé de pyridine
EA201370150A1 (ru) Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение
WO2005121130A3 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
DOP2010000165A (es) 4-(4-ciano-2-tioaril) dihidropirimidinonas y su uso como inhibidores de la elastasa neutrofila humana
NO20084328L (no) Nye forbindelser
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
CN109790155A (zh) 噻吩化合物及其合成方法和其在医药上的应用
JOP20210039B1 (ar) مركبات بيريدين 6،2 - ديامينو
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
WO2011006935A3 (en) Tetrazole derivatives
BR112015019412A2 (pt) inibidores de bace1
JP2016510326A5 (cg-RX-API-DMAC10.html)
CY1123346T1 (el) Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα
CR20240183A (es) Inhibidores y/o degradadores de bckdk
CN110167941A (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
CY1124383T1 (el) Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας
BR112022008384A2 (pt) Formulação oral de x842
EP3804728A4 (en) COMPOSITION WITH INOTODIOL COMPOUND AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF ALLERGY DISEASES
EA201992801A1 (ru) Способ получения соединения гетероциклического производного, композиции, содержащей указанное соединение, и гидрата указанного соединения
EA202092159A1 (ru) Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение